# Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Canonical URL: https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026
Ticker: ENTA
Company: Enanta Pharmaceuticals
Source: Enanta Pharmaceuticals
Published: 2026-05-04 11:00 EST
Original Source URL: https://ir.enanta.com
## Summary

WATERTOWN, Mass. --(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation

## Article Body
WATERTOWN, Mass. --(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation
## Recent Company News
- 2026-05-28 11:00 EST — [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference) — Source: Enanta Pharmaceuticals
- 2026-05-11 20:01 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026) — Source: Enanta Pharmaceuticals
- 2026-05-04 11:00 EST — [Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026) — Source: Enanta Pharmaceuticals
- 2026-04-13 11:00 EST — [Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria) — Source: Enanta Pharmaceuticals
- 2026-04-07 11:00 EST — [Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026) — Source: Enanta Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)